Phase II, open-label, multi-centre study of TP300 as a single agent as first line therapy in patients with advanced gastric cancer or gastroeosophageal junction adenocarcinoma. - TP103EU
100 Clinical Results associated with Chugai Pharma Europe Ltd
0 Patents (Medical) associated with Chugai Pharma Europe Ltd
100 Deals associated with Chugai Pharma Europe Ltd
100 Translational Medicine associated with Chugai Pharma Europe Ltd